Business Wire

Veristat Announces Global Cell and Gene Therapy Center of Excellence

22.10.2020 11:13:00 EEST | Business Wire | Press release

Share

Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat, a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.

“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”

Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:

  • The ability to develop your therapeutic with accelerated approval pathways and/or special designations
  • A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
  • Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
  • Expertise in logistics and handling of live cellular material
  • Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
  • Long-term follow-up strategies to meet global regulatory requirements

“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa30.4.2026 16:30:00 EEST | Press release

Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions. Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements. “Collaborati

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 16:22:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et

Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 16:00:00 EEST | Press release

Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity. “Agen

Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 16:00:00 EEST | Press release

Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant information, suggests next actions, and maintains conversational flow to keep every interaction effortless and engaging. Delivered in short, s

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye